← Leaderboards
Jennifer R. Diamond
University Of Colorado Denver
$1,231,780
Attributed
$1,231,780
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $329.9K · FY2012–17$500K$375K$250K$125K$0
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$1,231,780 · 2
By mechanism
K23$858,600 · 1
R21$373,180 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Paul A Bunn$21,859,370
- Madeleine A Kane$15,450,424
- Mary Elaine Reyland$13,618,689
- James V Degregori$21,700,379
- Christopher J Hogan$3,578,736
Others in their field
Top investigators on “Institution”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,187,810,557
- Leonard Freedman · Leidos Biomedical Research, Inc.$835,530,754
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$566,554,288
- Bambra Strokes · Ppd Development Lp$526,656,217
Research focus
InstitutionInvestigationEnrollmentInhibitor/AntagonistClinical TrialsCell LineDistant MetastasisEffective TherapyGenesGenomicsCessation Of LifeAurora KinaseBaseCell DivisionClinical EfficacyClinical ResearchBiologicalDrug KineticsFamilyBiopsyAreaCharacteristicsCancer CareKinase Inhibitor
Grant awards (7)
The Development of Novel Individualized Therapy for Triple-Negative Breast Cancer$171,720
K23 · FY2017 · CA · contact PI
The Development of Novel Individualized Therapy for Triple-Negative Breast Cancer$171,720
K23 · FY2016 · CA · contact PI
The Development of Novel Individualized Therapy for Triple-Negative Breast Cancer$171,720
K23 · FY2015 · CA · contact PI
The Development of Novel Individualized Therapy for Triple-Negative Breast Cancer$171,720
K23 · FY2014 · CA · contact PI
The Development of Novel Individualized Therapy for Triple-Negative Breast Cancer$171,720
K23 · FY2013 · CA · contact PI
The Development of Novel Individualized Therapy for Metastatic Triple Negative B$158,143
R21 · FY2013 · CA · contact PI
The Development of Novel Individualized Therapy for Metastatic Triple Negative B$215,037
R21 · FY2012 · CA · contact PI